ராகுல் கக்கர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from ராகுல் கக்கர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In ராகுல் கக்கர் Today - Breaking & Trending Today
Jeep Wrangler vs Land Rover Defender 110 comparison autocarindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from autocarindia.com Daily Mail and Mail on Sunday newspapers.
Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Merck to acquire Pandion Therapeutics for $1.85bn Merck will gain a pipeline of immune modulators targeting autoimmune diseases Merck (MSD) has signed a deal to acquire Pandion Therapeutics for approximately $1.85bn, gaining access to a pipeline of immune modulators for the treatment of autoimmune diseases. Leading Pandion’s pipeline is an engineered IL-2 mutein fused to a protein backbone – known as PT101 – that is designed to selectively activate and expand regulatory T cells (Tregs) for the potential treatment of ulcerative colitis and other autoimmune diseases. Tregs can inhibit the activity of several different pro-inflammatory immune cell types, and are critical for self-tolerance of the immune system. The dysfunction of Tregs is associated with a number of autoimmune diseases. ....
Merck signs agreement to purchase Pandion Therapeutics pharmaceutical-business-review.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceutical-business-review.com Daily Mail and Mail on Sunday newspapers.
Merck to Acquire Rahul Kakkar-Led Pandion Therapeutics for $1.85 Billion Rahul Kakkar WATERTOWN, Mass.– Merck and Pandion Therapeutics, Inc. announced that the companies have entered into a definitive agreement, under which Merck, through a subsidiary, will acquire Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $60 per share in cash. This represents an approximate total equity value of $1.85 billion. “This acquisition builds upon Merck’s strategy to identify and secure candidates with differentiated and potentially foundational characteristics,” Dr. Dean Y. Li, president, Merck Research Laboratories, said in a statement. “Pandion has applied its TALON technology to develop a robust pipeline of candidates designed to re-balance the immune response with potential applications across a wide array of autoimmune diseases.” ....